Impax announced that the Food and Drug Administration (FDA) has approved Zomig (zolmitriptan) Nasal Spray for use in pediatric patients aged ≥12 years for the acute treatment of migraine with or without aura.
The approval was based on safety and efficacy data from clinical trials, which demonstrated that Zomig Nasal Spray 5 mg was significantly more effective in providing no headache pain, relief of headache, and other associated symptoms of migraine when treating migraine in pediatric patients compared to placebo.
Zomig Nasal Spray, a selective 5-HT1B/1D receptor agonist, is already indicated for the acute treatment of migraine with or without aura in adults. It is available in 2.5-mg and 5-mg single-use nasal spray units.
For more information visit Zomig.com.
This article originally appeared on MPR